BR112015030774A2 - novos compostos para o tratamento de câncer - Google Patents

novos compostos para o tratamento de câncer

Info

Publication number
BR112015030774A2
BR112015030774A2 BR112015030774A BR112015030774A BR112015030774A2 BR 112015030774 A2 BR112015030774 A2 BR 112015030774A2 BR 112015030774 A BR112015030774 A BR 112015030774A BR 112015030774 A BR112015030774 A BR 112015030774A BR 112015030774 A2 BR112015030774 A2 BR 112015030774A2
Authority
BR
Brazil
Prior art keywords
compounds
cancer treatment
new compounds
treatment
new
Prior art date
Application number
BR112015030774A
Other languages
English (en)
Inventor
Andreas Schall Dr
Antje Margret Wengner Dr
Benjamin Bader Dr
Detlef Stöckigt Dr
Dirk Kosemund Dr
Gerhard Siemeister Dr
Hans Briem Dr
Hartmut Schirok Dr
Philip Lienau Dr
Ulf Bömer Dr
Ulrich Lücking Dr
Volker Schulze Dr
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50897594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015030774(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112015030774A2 publication Critical patent/BR112015030774A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

novos compostos para o tratamento de câncer. a presente invenção está relacionada a novos compostos que mostram um efeito inibitório na quinase mps-1, aos métodos de preparação dos compostos citados, às composições farmacêuticas e às combinações que consistem nos compostos citados, ao uso desses compostos na fabricação de uma composição farmacêutica para tratamento ou profilaxia de uma doença, bem como aos compostos intermediários úteis no preparo desses compostos.
BR112015030774A 2013-06-10 2014-06-04 novos compostos para o tratamento de câncer BR112015030774A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13171171 2013-06-10
EP13198899 2013-12-20
PCT/EP2014/061530 WO2014198594A1 (en) 2013-06-10 2014-06-04 Novel compounds for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112015030774A2 true BR112015030774A2 (pt) 2017-07-25

Family

ID=50897594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030774A BR112015030774A2 (pt) 2013-06-10 2014-06-04 novos compostos para o tratamento de câncer

Country Status (25)

Country Link
US (1) US20160207928A1 (pt)
EP (1) EP3008061A1 (pt)
JP (1) JP2016521737A (pt)
KR (1) KR20160019426A (pt)
CN (1) CN105246891A (pt)
AU (1) AU2014280395A1 (pt)
BR (1) BR112015030774A2 (pt)
CA (1) CA2914668A1 (pt)
CL (1) CL2015003584A1 (pt)
CR (1) CR20150653A (pt)
CU (1) CU20150175A7 (pt)
DO (1) DOP2015000298A (pt)
EA (1) EA201501175A1 (pt)
HK (1) HK1219737A1 (pt)
IL (1) IL242546A0 (pt)
MX (1) MX2015017011A (pt)
NI (1) NI201500175A (pt)
PE (1) PE20160747A1 (pt)
PH (1) PH12015502747A1 (pt)
SG (1) SG11201509351UA (pt)
SV (1) SV2015005126A (pt)
TN (1) TN2015000542A1 (pt)
TW (1) TW201529560A (pt)
UY (1) UY35602A (pt)
WO (1) WO2014198594A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
KR102549952B1 (ko) 2017-02-13 2023-06-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 아미노트리아졸로피리딘
HUE058292T2 (hu) 2017-10-30 2022-07-28 Bristol Myers Squibb Co Aminoimidazopiridazinok mint kináz inhibitorok
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009128520A1 (ja) * 2008-04-18 2009-10-22 塩野義製薬株式会社 Ｐ１３ｋ阻害活性を有する複素環化合物
WO2009133127A1 (en) * 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
KR20110046503A (ko) * 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2011110575A1 (en) * 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2545135T3 (es) * 2011-04-06 2015-09-08 Bayer Pharma Aktiengesellschaft Imidazopiridinas sustituidas y compuestos intermedios de las mismas
AU2012244859B2 (en) * 2011-04-21 2017-06-08 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
CA2866450C (en) * 2012-03-07 2020-02-18 Merck Patent Gmbh Triazolopyrazine derivatives

Also Published As

Publication number Publication date
UY35602A (es) 2015-01-30
PH12015502747A1 (en) 2016-03-14
HK1219737A1 (zh) 2017-04-13
MX2015017011A (es) 2016-04-25
US20160207928A1 (en) 2016-07-21
DOP2015000298A (es) 2016-03-15
KR20160019426A (ko) 2016-02-19
EP3008061A1 (en) 2016-04-20
WO2014198594A1 (en) 2014-12-18
CN105246891A (zh) 2016-01-13
TN2015000542A1 (en) 2017-04-06
SG11201509351UA (en) 2015-12-30
PE20160747A1 (es) 2016-08-25
CL2015003584A1 (es) 2016-06-24
SV2015005126A (es) 2017-01-30
JP2016521737A (ja) 2016-07-25
AU2014280395A1 (en) 2015-12-17
NI201500175A (es) 2016-01-06
CR20150653A (es) 2016-03-04
IL242546A0 (en) 2016-02-01
TW201529560A (zh) 2015-08-01
CA2914668A1 (en) 2014-12-18
EA201501175A1 (ru) 2016-10-31
CU20150175A7 (es) 2016-05-30

Similar Documents

Publication Publication Date Title
CO2017011851A2 (es) Compuestos novedosos
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
GT201400111A (es) Triazolopiridinas sustituidas
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112015026830A2 (pt) composto, composição farmacêutica, uso de um composto, método para profilaxia ou tratamento de um estado de doença ou condição
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
GT201500247A (es) Imidazopiridazinas sustituidas
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
BR112015018504A2 (pt) moduladores de flap
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
BR112015028096A2 (pt) forma cristalina de um hidrato, processo para a preparação da forma cristalina, composição farmacêutica, forma cristalina, combinação farmacêutica, hidrato cristalino e cristais
CR20160016A (es) Pirazolpiridinas sustituidas
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2517 DE 02-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]